Skip to content

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus Images

Pivotal Prospective Clinical Trial to Demonstrate the Efficacy and Safety of AEYE-DS Software Device for Automated Diabetic Retinopathy Detection From Digital Fundoscopic Images

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04612868
Enrollment
531
Registered
2020-11-03
Start date
2020-10-16
Completion date
2021-12-26
Last updated
2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Diabetic Retinopathy

Brief summary

AEYE-DS is a software device developed to increase compliance with diabetic retinopathy screening by automatically detecting more-than-mild diabetic retinopathy from digital fundus images using Artificial Intelligence (AI)-based software. This study has been designed to validate the safety and efficacy of the device at primary care and other point of care sites.

Interventions

DEVICEAEYE Software Device

Eligible participants will undergo the following procedures: * Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. * Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. * All study subjects will have their pupils dilated using dilation drops.

Sponsors

AEYE Health Inc
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥22 * Male or female * Documented diagnosis of diabetes mellitus, meeting the criteria established by the American Diabetes Association (ADA) and World Health Organization (WHO). * Understand the study and volunteer to sign the informed consent

Exclusion criteria

* Uncorrectable vision loss (e.g., with the use of eyeglasses), blurred vision, or floaters. * Diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion. * History of laser treatment of the retina or injections into either eye, or any history of retinal surgery. * Currently participating in another investigational eye study and actively receiving investigational product for Diabetic Retinopathy (DR) or Diabetic Macular Edema (DME). * Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia or previous enucleation). * Participant is contraindicated for imaging by fundus imaging systems used in the study: 1. Participant is hypersensitive to light 2. Participant recently underwent photodynamic therapy (PDT) 3. Participant is taking medication that causes photosensitivity 4. Participant has a history of angle-closure glaucoma or narrow anterior chamber angles

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)1 daySensitivity and specificity of the AEYE-DS device to detect mtmDR on digital funduscopic images, acquired by the Topcon NW400 fundoscopy device, based on two macula-centered images (one image from each eye of the patient). Sensitivity and specificity were calculated by comparing the output results of the AEYE-DS device to the ground truth (diagnostic determination by an independent, blinded panel of expert ophthalmologists at a reading center). The worst of two eyes was compared with the AEYE-DS output at the participant level.

Secondary

MeasureTime frameDescription
Sensitivity and Specificity, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)1 daySensitivity and specificity of the AEYE-DS device to detect mtmDR from digital funduscopic images, acquired by the Topcon NW400 fundoscopy device, based on four images (one macula centered image and one optic disc centered image per eye). Sensitivity and specificity were calculated by comparing the output results of the AEYE-DS device to the ground truth (diagnostic determination by an independent, blinded panel of expert ophthalmologists at a reading center). The worst of two eyes was compared with the AEYE-DS output at the participant level.
Imageability, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)1 dayTo assess the imageability of AEYE-DS, defined as the percentage of participants with a diagnostic output (positive for more than mild DR or negative for more than mild DR) from the AEYE-DS device. Participants with no diagnostic output (i.e., AEYE-DS output of Insufficient Quality) lowers the imageability of the AEYE-DS.
Imageability, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)1 dayTo assess the imageability of AEYE-DS, defined as the percentage of participants with a diagnostic output (positive for more than mild DR or negative for more than mild DR) from the AEYE-DS device. Participants with no diagnostic output (i.e., AEYE-DS output of Insufficient Quality) lowers the imageability of the AEYE-DS.

Countries

United States

Participant flow

Participants by arm

ArmCount
AEYE Software Device
An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. AEYE Software Device: Eligible participants will undergo the following procedures: * Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. * Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. * All study subjects will have their pupils dilated using dilation drops.
468
Total468

Baseline characteristics

CharacteristicAEYE Software Device
Age, Continuous55 years
Ethnicity (NIH/OMB)
Hispanic or Latino
138 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
329 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
9 Participants
Race (NIH/OMB)
Black or African American
132 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
White
323 Participants
Region of Enrollment
Israel
28 Participants
Region of Enrollment
United States
440 Participants
Sex: Female, Male
Female
246 Participants
Sex: Female, Male
Male
222 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 0
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
0 / 0

Outcome results

Primary

Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)

Sensitivity and specificity of the AEYE-DS device to detect mtmDR on digital funduscopic images, acquired by the Topcon NW400 fundoscopy device, based on two macula-centered images (one image from each eye of the patient). Sensitivity and specificity were calculated by comparing the output results of the AEYE-DS device to the ground truth (diagnostic determination by an independent, blinded panel of expert ophthalmologists at a reading center). The worst of two eyes was compared with the AEYE-DS output at the participant level.

Time frame: 1 day

Population: Completed subjects with valid ground truth and AEYE-DS results

ArmMeasureGroupValue (NUMBER)
AEYE Software DeviceSensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)Sensitivity92.98 percentage of participants
AEYE Software DeviceSensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)Specificity91.36 percentage of participants
Secondary

Imageability, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)

To assess the imageability of AEYE-DS, defined as the percentage of participants with a diagnostic output (positive for more than mild DR or negative for more than mild DR) from the AEYE-DS device. Participants with no diagnostic output (i.e., AEYE-DS output of Insufficient Quality) lowers the imageability of the AEYE-DS.

Time frame: 1 day

ArmMeasureValue (NUMBER)
AEYE Software DeviceImageability, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)99.1 percentage of participants
Secondary

Imageability, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)

To assess the imageability of AEYE-DS, defined as the percentage of participants with a diagnostic output (positive for more than mild DR or negative for more than mild DR) from the AEYE-DS device. Participants with no diagnostic output (i.e., AEYE-DS output of Insufficient Quality) lowers the imageability of the AEYE-DS.

Time frame: 1 day

ArmMeasureValue (NUMBER)
AEYE Software DeviceImageability, Based on Two Macula-centered Images (One Image From Each Eye of the Patient)99.1 percentage of participants
Secondary

Sensitivity and Specificity, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)

Sensitivity and specificity of the AEYE-DS device to detect mtmDR from digital funduscopic images, acquired by the Topcon NW400 fundoscopy device, based on four images (one macula centered image and one optic disc centered image per eye). Sensitivity and specificity were calculated by comparing the output results of the AEYE-DS device to the ground truth (diagnostic determination by an independent, blinded panel of expert ophthalmologists at a reading center). The worst of two eyes was compared with the AEYE-DS output at the participant level.

Time frame: 1 day

Population: completed subjects with valid ground truth and AEYE-DS results

ArmMeasureGroupValue (NUMBER)
AEYE Software DeviceSensitivity and Specificity, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)Sensitivity94.74 percentage of participants
AEYE Software DeviceSensitivity and Specificity, Based on Four Images (One Macula Centered Image and One Optic Disc Centered Image Per Eye)Specificity88.64 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026